<SEC-DOCUMENT>0001213900-24-050849.txt : 20240607
<SEC-HEADER>0001213900-24-050849.hdr.sgml : 20240607
<ACCEPTANCE-DATETIME>20240607170704
ACCESSION NUMBER:		0001213900-24-050849
CONFORMED SUBMISSION TYPE:	S-8 POS
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20240607
DATE AS OF CHANGE:		20240607
EFFECTIVENESS DATE:		20240607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Jasper Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001788028
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				842984849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8 POS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-277674
		FILM NUMBER:		241030573

	BUSINESS ADDRESS:	
		STREET 1:		2200 BRIDGE PKWY SUITE #102
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		6505491400

	MAIL ADDRESS:	
		STREET 1:		2200 BRIDGE PKWY SUITE #102
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Amplitude Healthcare Acquisition Corp
		DATE OF NAME CHANGE:	20190912
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8 POS
<SEQUENCE>1
<FILENAME>ea0207285-s8pos_jasper.htm
<DESCRIPTION>POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">As filed with the Securities and Exchange Commission on June 7, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No. 333-263702</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No. 333-270361</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No. 333-277674</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POST EFFECTIVE AMENDMENT NO. 1 TO:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8 REGISTRATION STATEMENT NO. 333-263702</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8 REGISTRATION STATEMENT NO. 333-270361</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8 REGISTRATION STATEMENT NO. 333-277674</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNDER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE SECURITIES ACT OF 1933</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jasper Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84-2984849</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction
    of <BR>
    incorporation or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<BR>
    Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2200 Bridge Pkwy Suite #102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Redwood City, CA 94065&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices) (Zip
Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jasper Therapeutics, Inc. 2021 Equity Incentive
Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Full title of the plan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ronald Martell</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Executive Officer and President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jasper Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2200 Bridge Pkwy Suite #102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Redwood City, CA 94065</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(650) 549-1400&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address and telephone number, including
area code, of agent for service)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Copies to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jeffrey T. Hartlin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Samantha H. Eldredge</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Paul Hastings LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1117 S. California Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Palo Alto, California 94304<BR>
(650) 320-1800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="text-align: left; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: left; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="text-align: left; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging&nbsp;growth&nbsp;company</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Pursuant to Securities Act
Forms Compliance and Disclosure Interpretation 126.43 (&ldquo;C&amp;DI 126.43&rdquo;) published by the Securities and Exchange Commission
(the &ldquo;Commission&rdquo;), Jasper Therapeutics, Inc. (the &ldquo;Registrant&rdquo;) is filing this Post-Effective Amendment No.
1 to Registration Statements on Form S-8 (this &ldquo;Post-Effective Amendment&rdquo;) to the following registration statements on Form
S-8 (collectively, the &ldquo;Prior Registration Statements&rdquo;) filed by the Registrant with the Commission:</P>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">1)</TD><TD STYLE="text-align: left">Registration
                                            Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390022013605/ea151694-s8_jaspertherap.htm">Form S-8</A> (File No. 333-263702) filed on March 18, 2022, with respect to 594,293
                                            shares of the Registrant&rsquo;s voting common stock, $0.0001 par value per share (&ldquo;Common
                                            Stock&rdquo;), issued or issuable under the Jasper Therapeutics, Inc. 2021 Equity Incentive
                                            Plan (the &ldquo;2021 Plan&rdquo;);</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">2)</TD><TD STYLE="text-align: left">Registration
                                            Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390023018584/ea174776-s8_jasper.htm">Form S-8</A> (File No. 333-270361) filed on March 8, 2023, with respect to 152,182
                                            shares of Common Stock issued or issuable under the 2021 Plan; and</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">3)</TD><TD STYLE="text-align: left">Registration
                                            Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024020154/ea0200937-s8_jasper.htm">Form S-8</A> (File No. 333-277674) filed on March 5, 2024, with respect to 275,000
                                            shares of Common Stock issued or issuable under the 2021 Plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">On June 6, 2024, the Registrant&rsquo;s stockholders
approved the Jasper Therapeutics, Inc. 2024 Equity Incentive Plan (the &ldquo;2024 Plan&rdquo;), which replaces the 2021 Plan. No further
awards will be made under the 2021 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
number of shares of Common Stock initially authorized for issuance pursuant to the awards under the 2024 Plan is equal to (a) 2,000,000
shares of Common Stock, plus (b) up to 766,591 </FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">shares of Common
Stock currently subject to outstanding stock options or other equity awards granted under the 2021 Plan that would become available for
future issuance under the 2024 Plan to the extent that, after the date hereof, any such equity award terminates or expires prior to exercise
or settlement, is not issued because the award is settled in cash or is forfeited because of the failure to vest (such shares under clause
(b), the &ldquo;Carryover Shares&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Contemporaneously with the filing of this Post-Effective
Amendment, the Registrant is filing a Registration Statement on Form S-8 to register the 2,000,000 newly authorized shares of Common
Stock that have become available for offer or sale pursuant to the 2024 Plan, which number does not include the Carryover Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; background-color: white">In accordance with C&amp;DI
126.43 and pursuant to the undertaking in Item 512(a)(1)(iii) of Regulation S-K that the Registrant disclose a material change in the
plan of distribution as it was originally disclosed in the Prior Registration Statements, this Post-Effective Amendment is filed to indicate
that the Prior Registration Statements will also cover the issuance of the Carryover Shares under the 2024 Plan (as such shares would
no longer be issuable under the 2021 Plan as described above). No additional securities are being registered by this Post-Effective Amendment.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; background-color: white">All information in this
Post-Effective Amendment gives effect to the 1-for-10 reverse stock split of the Common Stock that was effected on January 4, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>INFORMATION REQUIRED
IN THE SECTION 10(a) PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 24.5pt">The information specified
in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Post-Effective Amendment in accordance with the provisions of Rule 428
under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and the introductory note to Part I of Form S-8. The
document(s) containing the information specified in Part I will be sent or given to participants in the equity plans covered by this
Post-Effective Amendment as specified by Rule 428(b)(1) of the Securities Act.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">The following documents filed
by the Registrant with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) are hereby incorporated by reference into
this Registration Statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024020114/f10k2023_jaspertherap.htm">Form 10-K</A> for the year ended December 31, 2023, filed with the Commission on March 5, 2024;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
    Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024042805/ea0205836-10q_jasper.htm">Form 10-Q</A> for the quarter ended March 31, 2024 filed with the Commission on May 14, 2024; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information specifically
    incorporated by reference into the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 from
    the Registrant&rsquo;s revised definitive proxy statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024034831/ea0204165-02.htm">Schedule 14A</A>, filed with the Commission on April 22, 2024; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
    Current Reports on Form 8-K filed with the Commission on <A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024000980/ea191024-8k_jasper.htm">January 4, 2024</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024010267/ea192943-8k_jasper.htm">February 6, 2024</A>; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of the
    Registrant&rsquo;s common stock set forth in the Registration Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390019023846/f8a12b111819_amplitudehealth.htm">Form 8-A</A> filed with the Commission on November 18, 2019
    (File No. 001-39138) pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
    including any amendments or reports filed for the purpose of updating such description, including the description of the Registrant&rsquo;s
    common stock included as <A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024020114/f10k2023ex4-3_jasper.htm">Exhibit 4.3</A> to the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2023, filed
    with the Commission on March 5, 2024.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">All other reports and other
documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the filing
of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then
remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration
Statement from the date of the filing of such reports and documents, except as to any portion of any future annual or quarterly report
to stockholders or document or current report furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">For the purposes of this
Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be
deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document that
also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or
superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">You should rely only on the
information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized
anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related
prospectus is accurate as of any date other than the date on the front of the document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">You may contact the Registrant
in writing or orally to request copies of the above-referenced filings, without charge (excluding exhibits to such documents unless such
exhibits are specifically incorporated by reference into the information incorporated into this Registration Statement). Requests for
such information should be directed to:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jasper Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2200 Bridge Pkwy Suite #102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Redwood City, CA 94065</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(650) 549-1400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM&nbsp;4. DESCRIPTION OF SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM&nbsp;5. INTERESTS OF NAMED EXPERTS AND COUNSEL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Section 102 of the General
Corporation Law of the State of Delaware (&ldquo;DGCL&rdquo;) permits a corporation to eliminate or limit the personal liability of directors
of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where
the director breached his or her duty of loyalty to the corporation or its stockholders, failed to act in good faith, engaged in intentional
misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase or redemption in violation
of the DGCL or derived an improper personal benefit. The Registrant&rsquo;s second amended and restated certificate of incorporation
(the &ldquo;Amended and Restated Certificate of Incorporation&rdquo;) provides that no director of the Registrant shall be personally
liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of
law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for
breaches of fiduciary duty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Section 145 of the DGCL provides
that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request
of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses
(including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in
connection with an action, suit or proceeding to which he or she was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he or
she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of
the corporation, no indemnification shall be made with respect to judgments, fines and amounts paid in settlement in connection with
such action, suit or proceeding or with respect to any claim, issue or matter as to which such person shall have been adjudged to be
liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite
the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity
for such expenses which the Court of Chancery or such other court shall deem proper. The Amended and Restated Certificate of Incorporation
permits the Registrant to indemnify its directors, officers, employees and other agents to the maximum extent permitted by the DGCL,
and the Registrant&rsquo;s second amended and restated bylaws (the &ldquo;Amended and Restated Bylaws&rdquo;) provide that the Registrant
will indemnify its directors and officers and permit the Registrant to indemnify its employees and other agents, in each case to the
extent not prohibited by the DGCL or any other applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Registrant has entered,
and expects to continue to enter, into indemnification agreements with its directors and officers, that may be broader than the specific
indemnification provisions contained in the DGCL. These agreements, among other things, require the Registrant to indemnify each director
and officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&rsquo; fees, judgments,
penalties, fines and settlement amounts actually and reasonably incurred by the director or executive officer in any action or proceeding,
including any action or proceeding by or in right of the Registrant, arising out of the person&rsquo;s services as a director or executive
officer. These indemnification agreements also require the Registrant to advance all expenses incurred by the directors and executive
officers in investigating or defending any such action, suit or proceeding, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Amended and Restated
Bylaws provide that the Registrant may purchase insurance on behalf of any person required or permitted to be indemnified to the extent
permitted by the DGCL or any other applicable law. The Registrant has obtained insurance under which, subject to the limitations of the
insurance policies, coverage is provided to the Registrant&rsquo;s directors and executive officers against loss arising from claims
made by reason of breach of fiduciary duty or other wrongful acts as a director or executive officer, including claims related to various
liabilities arising under the Securities Act and the Exchange Act and to the Registrant with respect to payments that may be made by
the Registrant to these directors and executive officers pursuant to the Registrant&rsquo;s indemnification obligations or otherwise
as a matter of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 8. EXHIBITS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/ea147929ex3-1_jasper.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report
    on Form 8-K filed by the Registrant on September 29, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390023047446/ea179979ex3-1_jasper.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Amendment to the Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit
    3.1 to the Current Report on Form 8-K filed by the Registrant on June 8, 2023).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024000980/ea191024ex3-1_jasper.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Second Amendment to the Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference
    to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on January 4, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390023012596/ea173877ex3-1_jasper.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by
    the Registrant on February 17, 2023).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390019024606/f8k1119ex4-1_amplitude.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant Agreement, dated November 19, 2019, by and between the Registrant and Continental Stock Transfer &amp; Trust Company,
    as warrant agent (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Registrant on November
    25, 2019).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390019022224/fs12019a1ex4-3_amplitude.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen
    Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1/A (File No. 333-234324) filed
    by the Registrant on November 6, 2019).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024050751/ea020728501ex4-3_jasper.htm">Jasper Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-8 (File No. 333-280039) filed by the Registrant on June 7, 2024).</A>&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024050751/ea020728501ex4-4_jasper.htm">Form of Stock Option Award Agreement under the Jasper Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form S-8 (File No. 333-280039) filed by the Registrant on June 7, 2024).</A>&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024050751/ea020728501ex4-5_jasper.htm">Form of Restricted Stock Unit Award Agreement under the Jasper Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-8 (File No. 333-280039) filed by the Registrant on June 7, 2024).</A>&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024050751/ea020728501ex4-6_jasper.htm">Form of Restricted Stock Award Agreement under the Jasper Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 4.6 to the Registration Statement on Form S-8 (File No. 333-280039) filed by the Registrant on June 7, 2024).</A>&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea020728502ex5-1_jasper.htm">Opinion of Paul Hastings LLP.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390022013605/ea151694ex5-1_jaspertherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Paul Hastings LLP (previously filed on March 18, 2022 as Exhibit 5.1 to the Registrant&rsquo;s Registration Statement on Form
    S-8 (File No. 333-263702) and incorporated herein by reference).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390023018584/ea174776ex5-1_jasper.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Paul Hastings LLP (previously filed on March 8, 2023 as Exhibit 5.1 to the Registrant&rsquo;s Registration Statement on Form S-8
    (File No. 333270361) and incorporated herein by reference).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024020154/ea0200937ex5-1_jasper.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Paul Hastings LLP (previously filed on March 5, 2024 as Exhibit 5.1 to the Registrant&rsquo;s Registration Statement on Form S-8
    (File No. 333-277674) and incorporated herein by reference).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/ea147929ex10-3_jasper.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jasper
    Therapeutics, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed
    by the Registrant on September 29, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/ea147929ex10-4_jasper.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jasper
    Therapeutics, Inc. 2021 Equity Incentive Plan Form of Stock Option Grant Notice and Stock Option Agreement (incorporated by reference
    to Exhibit 10.4 to the Current Report on Form 8-K filed by the Registrant on September 29, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: -0.125in; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/ea147929ex10-5_jasper.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jasper
    Therapeutics, Inc. 2021 Equity Incentive Plan Form of RSU Award Grant Notice and Award Agreement (RSU Award) (incorporated by reference
    to Exhibit 10.5 to the Current Report on Form 8-K filed by the Registrant on September 29, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea020728502ex23-1_jasper.htm">Consent of PricewaterhouseCoopers LLP.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea020728502ex5-1_jasper.htm">Consent of Paul Hastings LLP (included in Exhibit 5.1).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390022013605/ea151694ex5-1_jaspertherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Paul Hastings LLP (included in Exhibit 5.2).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390023018584/ea174776ex5-1_jasper.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Paul Hastings LLP (included in Exhibit 5.3).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1788028/000121390024020154/ea0200937ex5-1_jasper.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Paul Hastings LLP (included in Exhibit 5.4).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 6.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney is contained on the signature page.</FONT></A></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 5.5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 9. UNDERTAKINGS. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) The Registrant hereby undertakes:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(1) To file, during any period in which offers
or sales are being made, a post-effective amendment to this Registration Statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(i) To include any prospectus required by Section&nbsp;10(a)(3)
of the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(ii) To reflect in the prospectus any facts or
events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually
or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the
foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more
than a 20&nbsp;percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo;
table in the effective registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(iii) To include any material information with
respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information
in this Registration Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><I>Provided, however, that:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(A) paragraphs (a)(1)(i) and (a)(1)(ii) do not
apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with
or furnished to the SEC by the Registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated
by reference in this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(2) That, for the purpose of determining any
liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial&nbsp;<I>bona fide</I>&nbsp;offering
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(3) To remove from registration by means of a
post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(b) The Registrant hereby undertakes that, for
purposes of determining any liability under the Securities Act, each filing of the Registrant&rsquo;s annual report pursuant to Section&nbsp;13(a)
or Section&nbsp;15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial&nbsp;<I>bona fide</I>&nbsp;offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(h) Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing
provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in Redwood City, State of California, on June 7, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jasper Therapeutics, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ronald
    Martell</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald Martell</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>POWER OF ATTORNEY</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Know
All Persons By These Presents</B></FONT>, that each person whose signature appears below constitutes and appoints Ronald Martell and
Herb Cross, and each or any one of them, as his or her true and lawful attorneys-in-fact and agent, with full power of substitution and
resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including
post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power
and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to
all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and
agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TITLE</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 21%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATE</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Ronald Martell</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive
    Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    7, 2024</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald Martell</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Herb Cross</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    7, 2024</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Herb Cross</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Accounting and
    Financial Officer)</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Thomas G. Wiggans</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairperson of the Board</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    7, 2024</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas G. Wiggans</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Scott Brun, M.D.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    7, 2024</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott Brun, M.D.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Anna French, D.Phil.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    7, 2024</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anna French, D.Phil.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Vishal Kapoor</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 7, 2024</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vishal Kapoor</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Christian W. Nolet</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    7, 2024</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christian W. Nolet</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Judith Shizuru, M.D., Ph.D.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    7, 2024</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judith Shizuru, M.D., Ph.D.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Kurt von Emster</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    7, 2024</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kurt von Emster</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>










<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">II-5</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea020728502ex5-1_jasper.htm
<DESCRIPTION>OPINION OF PAUL HASTINGS LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="text-align: left; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"><IMG SRC="ex5-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: left; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; text-align: left; width: 52%; padding-right: 0pt; padding-left: 0pt; font-size: 10pt">June 7, 2024</TD>
    <TD STYLE="text-indent: 0pt; width: 48%; padding-right: 0pt; padding-left: 0pt; text-align: right; font-size: 10pt">46931.00001</TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jasper Therapeutics, Inc.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2200 Bridge Pkwy Suite #102</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Redwood City, CA 94065</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">Re: Post-Effective
Amendment No. 1 to Registration Statements on Form S-8</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We have acted as counsel to Jasper Therapeutics,
Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the Post-Effective Amendment No 1 to Registration
Statements on Form S-8 (the &ldquo;<B><I>Post-Effective Amendment</I></B>&rdquo;) to be filed by the Company with the U.S. Securities
and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) on or about the date hereof under the Securities Act of 1933, as
amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;). The Post-Effective Amendment provides for the registration of up to a maximum
of 766,591 shares (such Shares, the &ldquo;<B><I>Carryover Shares</I></B>&rdquo;) of the Company&rsquo;s common stock, $0.0001 par
value per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;), which is a portion of the shares of Common Stock previously registered pursuant
to the following registration statements, that may become available for issuance pursuant to the Company&rsquo;s 2024 Equity Incentive
Plan (the &ldquo;<B><I>2024 Plan</I></B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.5in">(1)</TD><TD STYLE="text-align: left">Registration
                                            Statement on Form S-8 (File No. 333-263702) filed on March 18, 2022, with respect to 594,293
                                            shares of Common Stock issued or issuable under the Jasper Therapeutics, Inc. 2021 Equity
                                            Incentive Plan, as amended (the &ldquo;<B><I>2021 Plan</I></B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.5in">(2)</TD><TD STYLE="text-align: left">Registration
                                            Statement on Form S-8 (File No. 333-270361) filed on March 8, 2023, with respect to 152,182
                                            shares of Common Stock issued or issuable under the 2021 Plan; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.5in">(3)</TD><TD STYLE="text-align: left">Registration
                                            Statement on Form S-8 (File No. 333-277674) filed on March 5, 2024, with respect to 275,000
                                            shares of Common Stock issued or issuable under the 2021 Plan (the registration statements
                                            listed in (1) through (3) are referred to herein as the &ldquo;<B><I>Registration Statements</I></B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Carryover Shares will become available for issuance
pursuant to the 2024 Plan to the extent that any such Carryover Shares are subject to awards previously granted under the 2021 Plan and,
after the date hereof, any such equity award terminates or expires prior to exercise or settlement, is not issued because the award is
settled in cash, is forfeited because of the failure to vest or is reacquired or withheld (or not issued) to satisfy a tax withholding
obligation or the purchase or exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As such counsel and for purposes of our opinion
set forth below, we have examined and relied upon originals or copies, certified or otherwise identified to our satisfaction, of such
documents, resolutions, certificates and instruments of the Company and corporate records furnished to us by the Company, and have reviewed
certificates of public officials, statutes, records and such other instruments and documents as we have deemed necessary or appropriate
as a basis for the opinion set forth below, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 37pt"></TD><TD STYLE="text-align: left; width: 35pt">(i)</TD><TD STYLE="text-align: left">the Post-Effective
                                            Amendment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: right; text-indent: -35pt"><IMG SRC="ex5-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -35pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="ex5-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jasper Therapeutics, Inc.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">June 7, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 37pt"></TD><TD STYLE="text-align: left; width: 35pt">(ii)</TD><TD STYLE="text-align: left">the Registration
                                            Statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 37pt"></TD><TD STYLE="text-align: left; width: 35pt">(iii)</TD><TD STYLE="text-align: left">the Second
                                            Amended and Restated Certificate of Incorporation of the Company, certified by the Office
                                            of the Secretary of State of the State of Delaware on June 7, 2024;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 37pt"></TD><TD STYLE="text-align: left; width: 35pt">(iv)</TD><TD STYLE="text-align: left">the Third
                                            Amended and Restated Bylaws of the Company, as presently in effect, as certified by an officer
                                            of the Company on June 7, 2024;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 37pt"></TD><TD STYLE="text-align: left; width: 35pt">(v)</TD><TD STYLE="text-align: left">the 2021
                                            Plan and the forms of award agreements related thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 37pt"></TD><TD STYLE="text-align: left; width: 35pt">(vi)</TD><TD STYLE="text-align: left">the 2024
                                            Plan and the forms of award agreements related thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 38pt"></TD><TD STYLE="text-align: left; width: 34pt">(vii)</TD><TD STYLE="text-align: left">a certificate,
                                            dated as of June 7, 2024, from the Office of the Secretary of State of the State of Delaware,
                                            as to the existence and good standing of the Company in the State of Delaware (the &ldquo;<B><I>Good
                                            Standing Certificate</I></B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 38pt"></TD><TD STYLE="text-align: left; width: 34pt">(viii)</TD><TD STYLE="text-align: left">the
                                            resolutions adopted by the board of directors of the Company regarding the 2024 Plan and
                                            other matters related thereto, as certified by an officer of the Company on June 7, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In addition to the foregoing, we have made such
investigations of law as we have deemed necessary or appropriate as a basis for the opinion set forth in this opinion letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In such examination and in rendering the opinion
expressed below, we have assumed, without independent investigation or verification: (i) the genuineness of all signatures on all agreements,
instruments, corporate records, certificates and other documents submitted to us; (ii) the authenticity and completeness of all agreements,
instruments, corporate records, certificates and other documents submitted to us as originals; (iii) that all agreements, instruments,
corporate records, certificates and other documents submitted to us as certified, electronic, facsimile, conformed, photostatic or other
copies conform to originals thereof, and that such originals are authentic and complete; (iv) the legal capacity and authority of all
persons or entities (other than the Company) executing all agreements, instruments, corporate records, certificates and other documents
submitted to us; (v) the due authorization, execution and delivery of all agreements, instruments, corporate records, certificates and
other documents by all parties thereto (other than the Company); (vi) that no documents submitted to us have been amended or terminated
orally or in writing except as has been disclosed to us in writing; (vii) that the statements contained in the certificates and comparable
documents of public officials, officers and representatives of the Company and other persons on which we have relied for the purposes
of this opinion letter are true and correct; (viii) that there has not been any change in the good standing status of the Company from
that reported in the Good Standing Certificate; and (ix) that each of the officers and directors of the Company has properly exercised
his or her fiduciary duties. As to all questions of fact material to this opinion letter, and as to the materiality of any fact or other
matter referred to herein, we have relied (without independent investigation or verification) upon representations and certificates or
comparable documents of officers and representatives of the Company. Our knowledge of the Company and its legal and other affairs is
limited by the scope of our engagement, which scope includes the delivery of this opinion letter. We do not represent the Company with
respect to all legal matters or issues. The Company may employ other independent counsel and, to our knowledge, handles certain legal
matters and issues without the assistance of independent counsel. We have also assumed that the individual issuances, grants, awards
or grants of purchase rights under the 2024 Plan will be duly authorized by all necessary corporate action of the Company and duly issued,
granted or awarded and exercised in accordance with the requirements of law, the 2024 Plan and the agreements, forms of instrument, awards
and grants duly adopted thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="ex5-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jasper Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 7, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 3</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Based upon the foregoing, and in reliance thereon,
and subject to the assumptions, limitations, qualifications and exceptions set forth herein, we are of the opinion that the Carryover
Shares are duly authorized and, when issued and sold as described in the Registration Statements, as amended by the Post-Effective Amendment,
and in accordance with the 2024 Plan and the applicable award agreements (including the receipt by the Company of the full consideration
therefor), will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Without limiting any of the other limitations, exceptions
and qualifications stated elsewhere herein, we express no opinion with regard to the applicability or effect of the laws of any jurisdiction
other than the General Corporation Law of the State of Delaware, as in effect on the date of this opinion letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This opinion letter deals only with the specified
legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly stated herein from any matter addressed
in this opinion letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This opinion letter is rendered solely in connection
with the issuance and delivery of the Carryover Shares as described in the Post-Effective Amendment and in accordance with the terms
of the 2024 Plan and the applicable award agreement or form of instrument evidencing purchase rights thereunder. This opinion letter
is rendered as of the date hereof, and we assume no obligation to advise you or any other person with regard to any change after the
date hereof in the circumstances or the law that may bear on the matters set forth herein even if the change may affect the legal analysis
or a legal conclusion or other matters in this opinion letter.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We hereby consent to the filing of this opinion
letter as Exhibit 5.1 to the Post-Effective Amendment. In giving such consent, we do not hereby admit that we are within the category
of persons whose consent is required under Section 7 of the Securities Act or the rules or regulations of the Commission thereunder.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Paul Hastings LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea020728502ex23-1_jasper.htm
<DESCRIPTION>CONSENT OF PRICEWATERHOUSECOOPERS LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We hereby consent to the incorporation by reference in this Amendment
No. 1 to the Registration Statements on Form S-8 (Nos. <FONT STYLE="background-color: white">333-263702, </FONT>333-270361, and 333-277674)
of Jasper Therapeutics, Inc. of our report dated March 5, 2024 relating to the financial statements which appears in Jasper Therapeutics,
Inc.&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Jose, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 7, 2024</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V +<# 2(  A$! Q$!_\0
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M)+V=15L\BX5+M<DU*I37++EE^\AHU.+E[OB1A,5B/I'Y'&AAZ]:68YSX-XK
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M_$>G:%I5\D=]IFA^'K2/3H[/PYIJ6MJNG!XY!/++/-),S#[0KY5_X4A\?O\
MH]'XH?\ AJ/V=/\ YU5'_"D/C]_T>C\4/_#4?LZ?_.JK'#8:A@Z%+"X6E"AA
MZ$%3HT:::A3@G)J,4Y2:2<Y/64G>3UU/2SC.,TX@S3'YWG>/Q.:9OFF)GB\P
MS'&3C4Q6,Q52-*$Z]><:5&,JDHT:46XTJ:M3@E%6UN?MB?LH^ ?VVO@!XQ_9
MN^*7B7XA^&/A[X]GT%O%4_PQU_3?#7B35+#P_K=CX@M]%DU75-!\10)H][J6
MFV+ZK:I8"2^M[?[(\Z6TUQ'+ZY\)?A=X+^"/PO\ AY\'?ASI*:'X"^%_@SPW
MX#\(:4K"1K+P]X6TFUT;2X[B?:C7=XUK:1RWU]*//OKUY[RX9YYY';Q?_A2'
MQ^_Z/1^*'_AJ/V=/_G54?\*0^/W_ $>C\4/_  U'[.G_ ,ZJDL+AXXF>,5&"
MQ52C##SQ%FZDJ%.<JD*5W)I4XU)RGRQC"\G>3FTK5/.\VJ9-A^'9YAB99'A,
MQQ.;X?*N>*P=+-,9AJ.#Q.8*G&E"4\55PF'HX9U:U:NX4*:IT8T(RJ*I!^VK
M^Q=\$/V^?@-K?[._Q^T_7+GP3J^M^'_$MIJGA74K71O%OAGQ'X:O?M6G:YX9
MU:]T[5[2PU![2;4=$NWN-,O8KG0]9U>P:(?:_-C]W^%_@*R^%?PV^'_PQTS7
M/$WB;3/AWX+\,>!]-\0^,]2AUGQ?K>G>%-%LM#L=3\4:Q;V6G1:OK][:V,4^
MKZH+&U;4+]Y[N2)9)GKP_P#X4A\?O^CT?BA_X:C]G3_YU5'_  I#X_?]'H_%
M#_PU'[.G_P ZJE'"X:.)J8V-&G'%U:-/#U<0DU4J4:4Y3I4YM2Y91ISG)P;@
MY1YFE/E?(.IGF;ULEPO#M7,<55R+ YCB\VP655)QGA,)F6/H4<+C<9AX2I.I
M1JXNAAZ%/$*GB(T:OL:=2>'=:*KGR=^VW_P1R_9&_;@^)6D_';Q--\4?@E^T
M1HUI96,'QW_9Z\:)\/\ X@:E:Z5:"PT>/Q#+<Z3KNC:O<:3IX&F6.M'2K;Q-
M%H\=KHO]NG2+#3[&T^9?#O\ P;Q_LK:IXV\,^,_VE/V@OVS/VS(/!]]!J&@^
M"/VD?C>WBOP*EQ PD4:AIFF>']'UB^MGD5/M&GKK]MIE_ 'LM4L;^RFFMY/U
M+_X4A\?O^CT?BA_X:C]G3_YU5'_"D/C]_P!'H_%#_P -1^SI_P#.JKS*W#F1
M8C$3Q5?*\+4KU:BJU9.-10K58NZJ5J$*\,/5J72;G4P\W)ZSYW=O[7+/&+Q1
MR?*,/D66<<9[@\LP6%G@<#2IU<'/$Y=@JD91E@\MS/$95B<XR["\LYQA0P.;
MX6G2C.4:$:$6HP^G["PL=*L;+2]+LK33=,TVTMK#3M.L+:&SL;"QLX4M[2RL
MK2W2.WM;2UMXXX+:V@CCA@AC2*)%154?F-^W7_P21_9F_P""@WQ,^&WQ<^,W
MBOXY^$O&WPJ\*ZCX0\)ZE\'OB#IO@<PZ9J>JS:O//<2W/A77KX:BEQ<W,,=U
M8WMB#:3R03Q3 (R?37_"D/C]_P!'H_%#_P -1^SI_P#.JH_X4A\?O^CT?BA_
MX:C]G3_YU5>AC,#@\?AWA,;AJ6)PSE3DZ-2+]GS4G>FTH3I-.#UCRRBET5DD
MODN'^)^(>%,UAGO#F<8[)LXA2Q5".98*K".*5''4W2QE-U*]#&1G'%4VX5_:
M4JCJ)R<I<TI2E^5'_$.1^QQ_T</^WW_XDPG_ ,P=?LS^SO\  SPO^S3\%/AW
M\"?!6M^-/$GA7X::$/#^BZY\1/$+>*_&FHVGVV[OO/\ $'B!K6Q_M*[$MY)&
MDB6=K##;)!;0010P1H//?^%(?'[_ */1^*'_ (:C]G3_ .=51_PI#X_?]'H_
M%#_PU'[.G_SJJYL#DF4Y95G6P& P^$JU(>RG4I*KS2I\RGR/GQ%56YHJ6D4[
MI:]'['$OB/QWQE@Z&7\4\4YKGN!PV)6,P^&Q\L$Z5+%*C4H*O#ZME6 G[14:
MM2G[U6<>6;_=MVE'ZJHKY5_X4A\?O^CT?BA_X:C]G3_YU5'_  I#X_?]'H_%
M#_PU'[.G_P ZJO4/BCZJHKY5_P"%(?'[_H]'XH?^&H_9T_\ G54?\*0^/W_1
MZ/Q0_P##4?LZ?_.JH ^JJ*^5?^%(?'[_ */1^*'_ (:C]G3_ .=51_PI#X_?
M]'H_%#_PU'[.G_SJJ /JJBOE7_A2'Q^_Z/1^*'_AJ/V=/_G54?\ "D/C]_T>
MC\4/_#4?LZ?_ #JJ /JJBOE7_A2'Q^_Z/1^*'_AJ/V=/_G54?\*0^/W_ $>C
M\4/_  U'[.G_ ,ZJ@#ZJHKY5_P"%(?'[_H]'XH?^&H_9T_\ G544 ?-__!);
M]K7XM?MG_LKWWQ@^- \*CQA;?%KQQX+C_P"$/T6XT'23HOA^U\/3Z>7L;G4M
M4<W@?4[D3SBY5)4$0$*,K%_T0\=ZU>>&_!'C+Q%IZP/?Z!X5\0ZU8I=(\MLU
MYI>D7E];+<1QR0R20&:!!,B2Q.\995D1B&'\J/\ P2&^%W_!1;QE^RCJ.K_L
MI_M1?!WX-_"]?B_XZLYO"'C[X/6_CW7)/%=O9^'#K>LIKDL,C1Z??QR6"6VG
M@E;=K::0;3,0?T:^('P(_P""S$'@+QO/KG[=W[-^H:+#X0\2RZO86G[.5I97
M=]ID>BWKW]G:WJVP:RN;FU66&"[ <VTKK,$8IBK<5S/6*5]M=-M-OU)3?+L]
MM]//S/KG_@E[^TQ\2OVNOV,OAM\=/BXOAM?'?B?5?'-CJI\*:3<:)HSP^'_&
M.LZ+I[0:=<ZCJCPR_8+.W2=ENBDLB&01HS-G]!:_'O\ X(1%&_X)J?!EHU*1
MMXD^*Q1"<E4/Q(\2%5)[E5P">^*[?_@L+^U;/^RU^Q=XZD\,7YMOBI\9O-^#
MOPRAMG!U*WU#Q387:^)O$=G#&WVH'PUX2BU:[M;RVCD-IK]QH$9'F74*.FKS
M<4OM-)=M?T'>T4WV/ASPY_P5Y^-.H?M?Z)K>I^&?!4'_  3E\<_M*>(_V4/!
M?Q173+F+79_'.BZ+9VUIXPN?$<^L1P0^']1\37%OJ@:\T2WL_P#A%KZ[ABF;
M4]"U"2+^C"OY /B'^TI_P3MUO_@E=I?["OAJ\^+R>//!?@#1_$7@_P 02? O
MQ]"#^T)H\DGBR^U_^TUTRTCMH?$WBR^\0>'Y]2GDF.G^&=?G3S;@6L3M^]O_
M  2S_:N;]KW]C;X:>/-;O1=?$GP?;GX7?%F.21GNSX[\&6MG:3ZQ=^9(\K2^
M+=$FT;Q;)(RQQ_:=:N;>) +8JM2CI=*R3:]5T>[WUOYB3UM>^E_3NO\ (L_\
M%$OVT?$7['WP[^'=M\,? =G\3OCU\>/B3H_PD^"O@G5KFYM-"O/%&K8,NK>(
M)K2:UNI=)TTRV-JUC:7VGW%[?ZK81F_L;1;N\M_ENX^%_P#P75M=(/C"W_:=
M_9 U3Q$EL=6;X0-\*KRU\/RSK";G_A%[?QJ=&CU5I'<?V?'>W%[:P&8B236(
MK?-Y7T__ ,%#?V5?A+^V!X,^''PR\4?&6V^!_P :=#\;Q>.OV=_&EEK6D6WB
MRU\;Z'"B7D>B^&K[5-*U'Q98/;3VLNHV>A7=GJFG7UMHNK6^H6[V0M[SY(B\
M$?\ !>+X+6T1T3XM?LA_M8Z3ID*6UIIOC/P_JWP_\8:I!;((XY-0O-+T_P '
MZ6U].@4O<3^*9Y))O,DNIY&8R2)6LK<M];\RW[6>UN_F#O=[VTM;\;];GU]_
MP3N_;4U_]L;X;^.Q\2_AS)\)/CO\$O'VH_"_XS^ $34?[*T_Q+IX<PZMX?EU
M,/=KH^IM;ZA:K8W-YJ%UINHZ5J-L]_J%J++4;V+]HWPY_P %0-4^*%[=?LK_
M !%_9!\,_" Z+HL>GZ7\8O#GQ)U/QPNO)%/_ &_<7=UX:L+K2FT^:=H/[-2&
M02I"C"=%D)+8?_!/S]O76OVL[WXR?"CXN_"2Z^!?[2W[/.NZ?HOQ7^'W]HKJ
M^AW$6JF]@T_7_#FH,!="VDNM+O+:[L+HWT4$)TJ_T[7=;L=5CEMOTHI/1O1+
MR>JUUTUV[:[#6JW?KL_Z[G\Y7P8_:2_X+$?'+]H+]I7]G#POX\_8HTGQC^RW
MJ'A/3O'>N>(/ _Q%C\+ZW/XSM]1N]';PI)IL^H:Q<1_9M,N9+HZKI>F- ?+C
M93(X6OV5_98TK]L#2?"?B6#]L?Q1\#/%?C23Q+YWA.]^!.E>+=)T.W\*'2K!
M&M-;A\6V]K<RZN-8349DDM(C!]BF@1Y&D79'^:/_  3T_P"4I_\ P6&_[&K]
MGW_U'O&-?N=3EO9)+2+T6NJ3WN*.U[OKU\VOT/S+^+G[67Q8\%?\%1/V4OV1
M-%'A;_A4?QC^#/Q*\=^,C>:+<7'BO^W?"VC_ !$OM*&DZVNI16]A8B?PMIGV
MFWDTRZ>9&NU$R&:-H?TOG=HX9I%QN2*1UW E=RH6&0""1D<@$$CH1UK\./VB
M?^4\?_!/W_LV?XV?^HW\:*_<6Z_X]KC_ *X3?^BVI222C;K%-^MV-=?7]$?S
MF_\ !-?_ (++?$7XU_%>R^#W[8&B>%/"J_%K5]5TW]GSXH^&] U'PMX6\0^*
M/#]__9.L?#G5&U'5-4L+O5+NY:T70=1L[FWD76YCX>U&WFN=9T)D_>CXX^,-
M7^'OP4^,'C[P^+,Z_P"!_A;\0/&&B#4('N; ZOX:\)ZOK6FB^MHY8)+BS-[9
M0BY@2>%Y8=\:RQLP<?SD_P#!/+]BWP%^W)_P23U[X6^*9$T+QAI'[0OQH\2_
M"/XC6\<G]L_#GQ_9:EI[:9K%G<6[1W;:1?.!8>)-+BE1=0TV4S0&#6+#2-1L
M/I/]GC]M'X@^.OV;?VP?V*/VO(YO#/[:O[.GP#^,&DZ]'J\@W?&3P+9?#K6H
M](^).@7Q"Q:Y?2:?/IUSKMU; IKEAJ.D^,K!I[?5]4@T:FDVVE:S2:\KI76O
M79]M^I*;2U>ZNGUO:]O\C]%O^"<'Q_\ B!^U+^Q5\#/CU\4O["_X3WXA:5XL
MO/$/_",Z9+H^A^=HOQ"\6^&;+[!IL][J$MLITS1;(S*UY-YESYTJE%D$:97[
M?'[<>C_L6^ _!YT?P3JOQ;^.GQF\3KX ^ OP<T)IH]0\<>+YFLX9;B\N(+>Z
MN+;0-%FU/2DU V5M<ZC?W^JZ1I%E#$=1EU+3O)_^"*?_ "C!_93_ .P!\0O_
M %<7Q$KYR_:>%E<?\%TO^"?5OXP\MO"]O^SW\5+OP8FJB/\ L@?$8V_Q0+/8
MFY(@_MQ;:VT!K<0YN_M2:3Y:F0P$))<S[+F=O39?UTN.[Y5W=E?UZG8Z?\./
M^"Y_C>Q7QEJO[1G[(?P4U35$%_!\'M/^%]YXSTOP[YC&1-#U7QC<6.O7LL\"
M[8+JZTO5_$-N2&DM;^?(:NX_9!_;R^-6I_M(^(/V$OVY?AUX4^&G[3NF>%Y/
M&_P[\5?#^\N[CX:_''P59P-+>:KX:M[^XO+NQU6"TM=0U9TCO);.YATSQ'87
M6G^&=8\-7.DW?Z$?M!ZY\</#?PB\7:U^SAX'\(_$?XS6::.?!W@WQUXA?PMX
M7UAI]?TNWUH:EK<<D!M/L7AZ;5M0M ;BW$][:V\!D;S!#+^/MA^VE^W!X&_;
M&_9+^$_[6O[)_P"RYX$U3X_>)_$/A/PKXQ\&^-G\<_$'1-"T?1[BYU^ZTNYB
MU"]N]$LS+JEK9C[6(K#4A?ZC;1&25+D(+5/2.SMLFK:W7=;@]&M7T\U\^Q^W
MWCSQGHGPX\#>,_B'XFDN(O#?@/PGXB\9^();6$7%U%HGA?1[S7-6DMK<O&)[
MA+"QN&AA,D8ED"H77=N'X;_!7XO?\%:_V_?!<7[17P/\>_L[?LD? ?Q;J&N+
M\)O#'BKP7/\ %/Q]XC\/:1K-_HR:UXGOKNSO;"TDDOK"[LWEM(-$\^6SDN+7
M0O[.EL[^]_;GXGVG@/4?ASXZTGXHWVCZ;\.-;\)Z]H/CF\\0:O;Z!HL7A;7M
M-N='UM=2UJZN;*#3+6>PO9[>2\>[M_)\T,LJ.%(_#GX8_L+_ /!1W]EGPG:>
M'?V ?VX?@_\ $+]FV5Y_$WPV\!?';PHFMVVG:#KTT^MQ67AOQOX8TGQ3%>Z9
MJ,E^]]'?:+>>'M#U6YNY]933;.:^G>11M9[7TLY)M>?E?U!WTWMUMN>N_ G]
MLS]K[X)_M7^%OV,?^"@WA[X<:U>_%'PGXC\5_!C]HWX0V>I:9X2\3?\ "):;
MJ6LZYHWBW1[J..#2[M+#2;Z-)(K#0;JPU%-,M9=*U2Q\1:=K,)7F$O\ P5$_
M:E_8]^)GA#P#_P %0/V?/ W@7P9XZT[7G\&?'?X#ZMJ/B/P[=W_AVR::[M+W
MPY>:CKEY/=WLS6%O<VT%[H.I:9_:NGWSZ!<:3+-=VA5.,GJHWTWC9I_Y>:!-
M=_E+='TC_P $:?V?/''[-/[(-_\ #OX@:CX4U/7;GXR?$#Q/'<^#M1U?4])&
MG:O:^'(+6)[G6] \-W@O4?3YS/$NGM B-$8[F4LZQ_IIX^TBZ\0>!/&N@V+V
M\=[K?A+Q'I%G)=/)':I=:EH][9V[W,D,-Q+';K+,C3/%!-(L89DAD8!&**F3
M]YOS_K\A[1^3_)GP1_P26^!OC']G;]A?X4_"[QW?>&M1\1:3JGQ!O[FZ\)7^
MJ:EHKPZMX\\07ELL%UK&B>'KYY4B<+.LFF1(DF5CDE7#GS'XA?LZ^/OVBO\
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@F'4=5O+PHHHE)IM)M);)-I?@_P 025M5=O6[UZ(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  = < # 2(  A$! Q$!_\0
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M;.YFU/4K*TGY7Q#^T-X'\/\ B/Q;X=&E>._$(^'E_H>E_$?6_"/@O6?$VC>
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M4D?6/#?B3Q)X#\:_\*9U[QMXGO\ QQ\#_#_PG^+4/@?X=:Y:_#O0M*^'BIX
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:1^(9+S3_ !2=4DL9[?\ 26B@+^2^[_@G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  J ) # 2(  A$! Q$!_\0
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GO-$N(,#R9]-FMI8L#8RTUM?HG9K1IW[7V\_O0-:^NJ>JM:W;<__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
